Tipsheet
What matters at India’s listed companies
Earnings · Pharmaceuticals · Mid cap

MedPlus profit jumps 46% as pharmacy margins expand

Net profit hit ₹2.20 billion on 12% revenue growth for FY26. The board also shuffled its top ranks.

2 earlier stories on Medplus Health Services Ltd.
Mkt cap₹10,031 cr
P/E45.67×
ROE8.64%
Debt / eq.0.00
₹2.20 billion FY26 consolidated net profit

What's new

  • FY26 net profit rose 46.1% to ₹2.20 billion on revenue of ₹68.92 billion.
  • The board re-appointed MD G. Madhukar Reddy for another five-year term from August 2026.
  • Two new independent directors joined; company secretary Manoj Kumar Srivastava resigned.

Why this matters

The profit growth significantly outpaced revenue growth, signalling a clear improvement in the company's cost structure. This is the financial performance that underpins the board's confidence to lock in the managing director for another five years.

What we're watching

  • Whether the improved margins can sustain into FY27.
  • The strategy from the two new independent directors.
  • The reason for the company secretary's exit and succession plan.

The full read

MedPlus grew revenue 12.3% to ₹68.92 billion in FY26. Net profit surged 46.1% to ₹2.20 billion. The profit line moved almost four times as fast as the top line, a clear signal that the pharmacy chain's costs are under tighter control. That operational strength is the backdrop for the board's concurrent moves: re-instating Managing Director G. Madhukar Reddy for a fresh five-year term and adding two independent directors. The company secretary, Manoj Kumar Srivastava, exited the same day. The results are the strongest yet from the mid-cap retailer, but the real test is whether the margin gains can hold as the chain continues to expand its physical footprint.

Questions answered

How did MedPlus achieve 46% profit growth on just 12% revenue growth?
The significant gap indicates the company's costs grew much slower than its sales. The company reported improved operational execution and higher margins on its retail pharmacy sales, which drove a disproportionate jump in profitability.
What were the key management changes announced?
The board re-appointed Managing Director G. Madhukar Reddy for a new five-year term starting August 2026. It also appointed two new independent directors to the board.
Who left the company?
Manoj Kumar Srivastava, the company secretary, resigned effective May 20, 2026. The filing did not state a reason.
Is the revenue growth figure for the full year or a quarter?
The headline figures are for the full fiscal year ended March 2026. The analyst rationale also noted healthy sequential growth in the fourth quarter.
Mentioned: G. Madhukar Reddy · Manoj Kumar Srivastava · ₹68.92 billion revenue
Primary source BSE · NSE · Tijori

An independent reading of the company's own disclosure — the primary filing above is the final word.

Company snapshot

Medplus Health Services Ltd.

Pharmaceuticals
₹11,794 cr
P/E 56.97×

Latest quarter · Mar 2026

Sales₹1,864 cr
Net profit₹64 cr
Op. margin+9.1%
EPS₹5.33

Strength & growth

Debt / equity0.00×
Current ratio3.03×
  1. 20 May 2026 · 9:18 PM IST MedPlus profit jumps 46% as pharmacy margins expand
  2. 46d ago MedPlus targets 800 new stores in FY27, private label margins recover
  3. 47d ago MedPlus profit jumps 46% to ₹2,196.1 mn, revenue up 12% to ₹68,924.6 mn